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Perspectives
Targeting the Epidermal Growth 
Factor Receptor Kinase in Cancer
During the last ﬁve years, kinase 
inhibitors have emerged as a promising 
new class of cancer therapeutics [1]. 
These drugs target enzymes that are 
often ubiquitously expressed within 
the human body, control a wide 
range of cellular responses, and are 
tightly regulated under physiological 
conditions [2]. Cancer cells can 
escape these normal restraints on 
kinase activity through mutations 
in kinase-encoding genes or genes 
regulating their function [3]. Even 
though tumorigenesis is a multistep 
process requiring multiple genetic 
aberrations, cancer cells can become 
so dependent on, or “addicted” to, a 
deregulated signaling pathway that 
blocking this signal results in cell death 
[4]. Oncogene addiction was ﬁrst 
documented in genetically engineered 
mouse models of cancer [5–7] and 
subsequently proven in the clinic by the 
dramatic response of BCR-ABL–positive 
leukemias to the small molecule ABL-
kinase inhibitor imatinib [8,9].
Among kinase candidates to be 
targeted in epithelial cancers, the 
epidermal growth factor receptor 
(EGFR) was one of the ﬁrst choices 
[10] based on the evidence in 
human tumor samples for oncogenic 
EGFR activation through EGFR
gene ampliﬁcation, gain-of-function 
deletions in the EGFR extracellular 
domain, and coexpression of EGFR 
and its ligands [11]. EGFR-targeted 
therapeutics have been explored in a 
large number of human malignancies 
and have shown clinical activity in 
subsets of patients with non-small cell 
lung cancer (NSCLC), glioblastoma, 
squamous cell carcinomas of the 
head and neck, colorectal carcinoma, 
and certain other malignancies [12]. 
The identiﬁcation of EGFR kinase 
domain mutations in patients with 
NSCLC, and the association of these 
mutations with clinical responses to 
EGFR tyrosine kinase inhibitors (TKI), 
constituted a landmark discovery for 
our understanding of EGFR-mediated 
oncogenesis [13–15].
Exactly how inhibition of EGFR 
signaling results in the often dramatic 
tumor responses of EGFR-mutant
lung tumors has remained an enigma. 
Three highly complementary studies 
published in this issue of PLoS Medicine
address this important question and 
identify the proapoptotic molecule 
BIM (BCL2-interacting mediator of 
cell death, also called BCL2-like 11) as 
critical mediator of EGFR TKI-induced 
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This Perspective discusses the following 
new studies published in PLoS Medicine:
▪ Gong Y, Somwar R, Politi K, Balak M, 
Chmielecki J, et al. (2007) Induction 
of BIM is essential for apoptosis 
triggered by EGFR kinase inhibitors 
in mutant EGFR-dependent lung 
adenocarcinomas. PLoS Med 
4(10): e294. doi:10.1371/journal.
pmed.0040294
Using a panel of human drug-sensitive 
EGFR mutant lung cancer cells, 
William Pao and colleagues show that 
induction of BIM, a member of the 
BCL2 family, is essential for apoptosis 
triggered by EGFR kinase inhibitors.
▪ Costa DB, Halmos B, Kumar A, 
Schumer ST, Huberman MS, et al. 
(2007) BIM mediates EGFR tyrosine 
kinase inhibitor-induced apoptosis 
in lung cancers with oncogenic EGFR 
mutations. PLoS Med 4(10): e315. 
doi:10.1371/journal.pmed.0040315
Susumo Kobayashi and colleagues 
provide evidence that the polypeptide 
BIM is involved in tyrosine kinase 
inhibitor (TKI)-induced apoptosis 
in sensitive EGFR-mutant cells and 
suggest that induction of BIM may 
have a role in the treatment of TKI-
resistant tumors.
▪ Cragg MS, Kuroda J, Puthalakath 
H, Huang DCS, Strasser A (2007) 
Geﬁtinib-induced killing of NSCLC 
cell lines expressing mutant EGFR
requires BIM and can be enhanced by 
BH3 mimetics. PLoS Med 4(10): e316. 
doi:10.1371/journal.pmed.0040316
Andreas Strasser and colleagues 
demonstrate that activation of the 
proapoptotic BH3-only protein BIM 
is essential for tumor cell killing and 
that shutdown of the EGFR–MEK–ERK 
signaling cascade is critical for BIM 
activation.
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cell death in EGFR-driven cancer 
[16–18].
What the Three New Studies Show
To study the mechanisms of EGFR 
TKI-induced cell death, all three 
research teams took advantage of the 
large number of NSCLC cell lines 
that have been characterized in terms 
of their EGFR mutational status and 
cytotoxic response to the EGFR TKIs 
geﬁtinib and erlotinib: H3255, PC-9, 
and HCC827 cell lines showed the 
most dramatic apoptotic responses; 
H1975, A549, and H460 cells were 
resistant; and H1650 cells showed an 
intermediate response. Cell death in 
response to EGFR kinase inhibition 
featured cytochrome c release and 
activation of BAX and could be 
rescued by overexpression of BCL-xL,
all consistent with activation of the 
mitochondrial “intrinsic” pathway of 
apoptosis.
Since activation of the intrinsic 
cell death pathway is governed by the 
balance between proapoptotic and 
antiapoptic BCL2 family members [19], 
the studies next looked for changes in 
the expression of BCL2 proteins that 
were most consistently correlated with 
the phenotype of EGFR TKI-induced 
apoptosis. Rapid dephosphorylation 
and increasing levels of the 
proapoptotic family member BIM, and 
in particular its splice variant BIMEL,
was observed in all cell lines with a 
cytotoxic response. This correlation 
between BIM induction and EGFR TKI 
induced cell death was not limited to 
the in vitro environment as shown by 
Yixuang Gong and colleagues using 
two distinct transgenic mouse models 
of EGFR-driven lung cancer [16]. In 
contrast to the ﬁndings with BIM, 
changes in the expression of other 
“BH3-only proteins” (BAD, PUMA, and 
BMF), BAX family members (BAX and 
BAK), or antiapoptotic BCL2 family 
members (BCL2, BCL-xL, BCL-w, and 
MCL1) were not consistently associated 
with apoptosis.
Daniel Costa and colleagues further 
explored the relationship between BIM 
induction and EGFR TKI response 
in isogenic cell lines and showed that 
stable overexpression of a geﬁtinib-
resistant EGFR allele (delE746-A750/
T790M) in HCC827 cells markedly 
attenuated BIM induction and 
apoptosis in response to geﬁtinib [17]. 
BIM induction and apoptosis were 
restored in these cells when geﬁtinib 
was switched to the irreversible EGFR 
kinase inhibitor CL-387,785 which 
does inhibit the delE746-A750/T790M 
EGFR allele. Costa and colleagues 
also described a new EGFR mutation 
(L747S) in a tumor with acquired 
EGFR kinase inhibitor resistance and 
showed that IL3-independent Ba/F3 
cells overexpressing this allele showed 
an intermediate degree of BIM1 
induction and intermediate levels of 
apoptosis in response to geﬁtinib (i.e., 
relative to the hypersensitive L858R 
mutant and the resistant L858R/
T790M mutant).
To prove the biological signiﬁcance 
of BIM induction for EGFR TKI-
induced cell death in EGFR-driven 
cells, all three groups demonstrated 
that RNA interference-mediated 
knockdown of BIM was sufﬁcient to 
block or at least markedly attenuate 
the apoptotic response to EGFR kinase 
inhibition.
Using BH3 proﬁling [28] of 
mitochondria from EGFR mutant cells, 
Jing Deng et al. similarly identiﬁed 
BIM as critical effector of EGFR TKI 
induced cell death [29].
Implications
Using RNAi technology and cells from 
gene-targeted mice, Junya Kuroda et al. 
recently demonstrated that BIM (and 
to lesser degree BAD) play a critical 
role in imatinib-induced apoptosis of 
BCR-ABL–positive leukemia cells [20]. 
The current studies demonstrate that 
activation of the intrinsic cell death 
pathway through induction of BIM 
is also required to elicit an apoptotic 
response to EGFR TKIs in NSCLC cells 
harboring mutant EGFR. While this 
observation remains to be formally 
proven in patients, it should be 
emphasized that the preclinical models 
used in these studies have a strong track 
record of predicting drug response and 
drug resistance in patients with NSCLC 
and EGFR mutations [13,21–24]. The 
current studies thus raise the question 
whether mutations in the intrinsic cell 
death pathway provide a mechanism of 
resistance to EGFR TKIs and perhaps 
other kinase inhibitors.
The level of BIM induction in 
EGFR mutant preclinical models 
appears to correlate with the extent 
of apoptosis and is inﬂuenced by drug 
concentration, EGFR genotype, and 
other unknown cellular factors. Since 
BIM functions by inhibiting BCL2 and 
its antiapoptotic homologs [25], it is 
perhaps not surprising that a BH3-
mimetic compound (ABT-737), which 
binds to BCL2, BCL-xL, and BCL-w, can 
synergize with low-dose EGFR kinase 
BCR-ABL: Fusion ofthe BCR (breakpoint 
cluster region) gene on Chromosome 22 
tothe ABL (Ableson leukemia virus) gene 
on Chromosome 9 is found in 95% of 
patients with chronic myeloid leukemia. 
The resultant fusion protein BCR-ABL is a 
constitutivelyactive cytoplasmic tyrosine 
kinase and the molecular target of the 
small molecule kinase inhibitor imatinib 
(Gleevec).
The BCL2 protein network: The family of 
BCL2 (B cell lymphoma 2)-related proteins 
in mammals includes at least 20 members 
that compete with each other to promote 
or block cell death in response to various 
forms of stress. BCL2-related proteins 
are usually grouped into three distinct 
categories: the antiapoptotic proteins 
(BCL2, BCL-xL, MCL1, BCL-w, and A1/Bﬂ-
1), the proapoptotic proteins (BAX and 
BAK), and the “BH3-only proteins” (BIM, 
BAD, PUMA, NOXA, BIK, and BID), which 
share a single motif (a BCL2-homology 3 
[BH3] domain) with other BCL2 proteins. 
BH3-only proteins promote cell death 
by inhibiting antiapoptotic BCL2 family 
members, which themselves restrain BAX 
and BAK activity. BAX and BAK activation 
result in permeabilization of the 
mitochondrial membrane, cytochrome 
c release, and the activation of caspases, 
which execute the cell-suicide program. 
The BIM mRNA undergoes alternative 
splicing to give rise to the short, long, and 
extra-long protein variants (BIMS, BIML,
and BIMEL).
Ba/F3 cells: Murine Ba/F3 pro-B 
lymphocytes provide a unique model 
system with which to examine kinase 
inhibitor sensitivity because stable 
expression of oncogenic kinases can 
relieve these cells from their intrinsic 
dependence on interleukin 3 (IL3) for 
survival. The Ba/F3 cells do not express 
endogenous EGFR and thus provide 
an opportunity to compare ectopically 
expressed EGFR mutants within the same 
cellular background.
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inhibitor therapy to induce apoptosis 
in EGFR-driven cells as shown by the 
Gong and Cragg groups [16,18]. This 
latter ﬁnding suggests that combining 
EGFR TKIs with a BH3-mimetic 
peptide might provide additional 
beneﬁt over EGFR TKI monotherapy 
in tumors with questionable drug 
penetration or certain EGFR genotypes.
The Gong and Cragg groups show 
that inhibitors of the EGFR effector 
kinase MEK1/2 phenocopy the 
effects of EGFR TKIs on BIM, but fail 
to trigger apoptosis [16,18]. These 
data suggest that BIM-independent 
EGFR signals are required to 
cause cell death in EGFR-mutant
NSCLC cells. Additional studies are 
needed to identify these signals and 
determine how speciﬁc oncoproteins 
modulate BIM and other BCL2 family 
members at the transcriptional and 
post-translational level [26,27]. By 
identifying critical effectors of kinase 
inhibitor–induced cell death, the 
recent studies have brought us one big 
step closer to unraveling the mysteries 
of oncogene addiction.  
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